ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.
At the CPHI, the world’s largest pharmaceutical event, which attracted 40,405 visitors this year, it became evident that the COVID-19 pandemic has had an extremely positive impact on the (bio)pharmaceutical sector. A new CPHI annual survey shows how business will develop in the future. Particularly, the prospects for CDMOs and CROs are excellent.
Unit-dose?The SARS-CoV2 pandemic caused 6.3 million deaths and contaminated 545 million people across the world. In spite of the rapid development and approval of vaccines, the shortages of consumables like glass vials limited the distribution of prophylactic vaccines. Blow-Fill-Seal (BFS) is an alternative solution with advantages that could play an important role in vaccine distribution worldwide.
According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. This would be the largest acquisition in the company’s history.
The French company Standing Ovation uses precision fermentation to create the protein that gives cheese its unique properties. With his pitch, co-founder and CEO Frédéric P’ques took the prize at the start-up pitch of the Industria Biotech.
Sino Biological and Ainnocence have joined forces to establish an AI-enabled platform for antibody affinity maturation.
With a new expansion coming online in Copenhagen, AGC Biologics is offering more capacity in Europe for mammalian biologics projects using innovative single-use bioreactor technology. This is the latest in a string of new investments from the global CDMO to expand capacity and upgrade technology at its sites in Europe, Japan and the United States.
The Covid-19 pandemic has changed perception of the value of rapid vaccine production, followed by multi-billion investments across the globe. While nanomedicines are receiving attention for enhancing stability and targeted activity of APIs, their broad availability currently suffers from the same production bottleneck as mRNA vaccines. Leon-nanodrugs, a pharma technology company, is developing a disruptive approach to unlock high-speed vaccine production.
Vienna is one of Europes most dynamic innovation hubs in the life sciences. End of September, the life science community met to celebrate LISAvienna. For 20 years, LISAvienna has been acting as the clusters central point of contact. In close collaboration with Austrias support and funding ecosystem, the platform accompanies and supports bioentrepreneurs through the ups and downs of their journey to transfer innovative business ideas into viable products and services.
Viral Vectors?Commercial-scale manufacturing demands a high yield of potent rAAV products. Understanding the metabolism during cell growth, especially at high densities, molecular effects of transfection or infection in production is vital. In addition, the choice of producer cell type determines the PTMs of the AAV capsid and potency. Successful trials in tweaking cell factories genes to boost rAAV particle yields set the direction for further development.